In­ven­tis­Bio reels in $147M to push gout and breast can­cer drugs along

A year and a half af­ter land­ing a $70 mil­lion Se­ries C round, Shang­hai-based In­ven­tis­Bio has more than dou­bled that amount in a hefty Se­ries D.

Mer­ck vet Yaolin Wang launched In­ven­tis “from scratch” back in 2015. In 2017, the biotech had 7 staffers, a $19 mil­lion Se­ries B and an am­bi­tious two- to three-year time­line to its first ap­proval. While the com­pa­ny has yet to snag a reg­u­la­to­ry OK, its lead can­di­date tar­get­ing EGFR T790M mu­ta­tions is cur­rent­ly in reg­is­tra­tional tri­als as a first- and sec­ond-line treat­ment in non-small cell lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER